Jazz Pharmaceuticals PLC
JAZZ: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| kjZ | LOCK|Lt | LOCK|TJZdtVx |
Jazz: Ziihera's Positive Survival Data Supports Growth Beyond Core Sleep Franchise
Jazz presented analysis from its study of Ziihera in HER2-positive advanced gastroesophageal adenocarcinoma, demonstrating sustained survival benefit at three years. Ziihera plus tislelizumab and chemotherapy showed an improved overall survival hazard ratio of 0.65.
